Research on racial differences in Alzheimer disease (AD) dementia has increased in recent
years. Older African American individuals bear a disproportionate burden of AD and …

Meaningful reductions in racial and ethnic inequities in chronic diseases of aging remain
unlikely without major advancements in the inclusion of minoritized populations in aging …

Abstract The coronavirus disease 19 (COVID‐19) pandemic has created significant and new
challenges for the conduct of clinical research involving older adults with Alzheimer's …

Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are
currently conducted only in research settings. Yet, US Food and Drug Administration …

Abstract Introduction Black Americans are disproportionately burdened by Alzheimer's
disease (AD) relative to other racial groups in the United States and continue to be …

Abstract The National Alzheimer's Project Act identifies the effective treatment and
prevention of Alzheimer's by 2025 as an urgent public health mission. This priority is …

Background: Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in
which abnormal biomarkers indicate risk for developing cognitive impairment. Research is …

Methods: Using linear regression, we assessed the relationship among enrollment
willingness and demographics, family dementia history, research attitudes, concern about …

Background Older adults, especially minoritized racial-ethnic groups, are historically
underrepresented in biomedical research. This study summarizes the development and …

Abstract Background Black/African Americans experience a high burden of Alzheimer
disease and related dementias yet are critically underrepresented in corresponding …